Highly selective end-tagged antimicrobial peptides derived from prelp

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Malmsten, Martin ^a   Kasetty, Gopinath ^b   Pasupuleti, Mukesh ^b   Alenfall, Jan ^c   Schmidtchen, Artur ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c Dermagen AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLINEAMIDE; ARGINYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLPHENYLALANYLP HENYLALANYLPHENYLALANINEAMIDE; ARGINYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLPHENYLALANYLP HENYLALANYLPHENYLALANYLPHENYLALANINEAMIDE; ARGINYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLPHENYLALANYLP HENYLALANYLPHENYLALANYLPHENYLALANYLPHENYLALANINEAMIDE; ARGINYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLPHENYLALANYLP HENYLALANYLPHENYLALANYLPHENYLALANYLPHENYLALANINECARBOXYLIC ACID; ARGINYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLTRYPTOPHANYLT RYPTOPHANYLTRYPTOPHANAMIDE; ARGINYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLTRYPTOPHANYLT RYPTOPHANYLTRYPTOPHANYLTRYPTOPHANAMIDE; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; GLYCYLARGINYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLINEAMIDE; GLYCYLARGINYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLINECARBOX YLIC ACID; GLYCYLARGINYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLPHENYLA LANYLPHENYLALANYLPHENYLALANINEAMIDE; GLYCYLARGINYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLPHENYLA LANYLPHENYLALANYLPHENYLALANINECARBOXYLIC ACID; GLYCYLARGINYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLPHENYLA LANYLPHENYLALANYLPHENYLALANYLPHENYLALANINEAMIDE; GLYCYLARGINYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLPHENYLA LANYLPHENYLALANYLPHENYLALANYLPHENYLALANINECARBOXYLIC ACID; GLYCYLARGINYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLPHENYLA LANYLPHENYLALANYLPHENYLALANYLPHENYLALANYLPHENYLALANINEAMIDE; GLYCYLARGINYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLPHENYLA LANYLPHENYLALANYLPHENYLALANYLPHENYLALANYLPHENYLALANINECARBOXYLIC ACID; GLYCYLARGINYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLTRYPTOP HANYLTRYPTOPHANYLTRYPTOPHANAMIDE; GLYCYLARGINYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLTRYPTOP HANYLTRYPTOPHANYLTRYPTOPHANCARBOXYLIC ACID; GLYCYLARGINYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLTRYPTOP HANYLTRYPTOPHANYLTRYPTOPHANYLTRYPTOPHANAMIDE; GLYCYLARGINYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLTRYPTOP HANYLTRYPTOPHANYLTRYPTOPHANYLTRYPTOPHANCARBOXYLIC ACID; GLYCYLARGINYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLARGINYLPROLYLTRYPTOP HANYLTRYPTOPHANYLTRYPTOPHANYLTRYPTOPHANYLTRYPTOPHANCARBOXYLIC ACID; LEUKOCYTE ELASTASE; OMIGANAN; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEINASE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; GLYCOPROTEIN; PRELP PROTEIN, HUMAN; SCLEROPROTEIN;

ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; EPITHELIUM CELL; ESCHERICHIA COLI; EX VIVO STUDY; HEMOLYSIS; HUMAN; HUMAN CELL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; SKIN INJURY; STAPHYLOCOCCUS AUREUS; SWINE; VANCOMYCIN RESISTANT ENTEROCOCCUS; WOUND INFECTION; AMINO ACID SEQUENCE; ANIMAL; CELL CULTURE; CHEMISTRY; DRUG EFFECT; INJURY; MICROBIOLOGY; MOUSE; PATHOGENICITY; PSEUDOMONAS INFECTION; SKIN; STAPHYLOCOCCUS INFECTION; WOUND HEALING;

MAMMALIA; NEGIBACTERIA; POSIBACTERIA; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

AMINO ACID SEQUENCE; ANIMALS; ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CELLS, CULTURED; EPITHELIAL CELLS; EXTRACELLULAR MATRIX PROTEINS; GLYCOPROTEINS; HUMANS; MICE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SKIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; WOUND HEALING;

EID: 79551517588     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016400     Document Type: Article

References (72)

1. Powers JP, Hancock RE (2003) The relationship between peptide structure and antibacterial activity. Peptides 24: 1681-1691.
2. Bulet P, Stocklin R, Menin L (2004) Anti-microbial peptides: from invertebrates to vertebrates. Immunol Rev 198: 169-184.
3. Yount NY, Bayer AS, Xiong YQ, Yeaman MR (2006) Advances in antimicrobial peptide immunobiology. Biopolymers 84: 435-458.
4. Durr UH, Sudheendra US, Ramamoorthy A (2006) LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta 1758: 1408-1425.
5. Zelezetsky I, Pontillo A, Puzzi L, Antcheva N, Segat L, et al. (2006) Evolution of the primate cathelicidin - correlation between structural variations and antimicrobial activity. J Biol Chem.
6. Tossi A, Sandri L, Giangaspero A (2000) Amphipathic, alpha-helical antimicrobial peptides. Biopolymers 55: 4-30.
7. Zelezetsky I, Tossi A (2006) Alpha-helical antimicrobial peptides-Using a sequence template to guide structure-activity relationship studies. Biochim Biophys Acta 1758: 1436-1449.
8. Ganz T (1999) Defensins and host defense. Science 286: 420-421.
9. Lehrer RI, Lichtenstein AK, Ganz T (1993) Defensins: antimicrobial and cytotoxic peptides of mammalian cells. Annu Rev Immunol 11: 105-128.
10. Agerberth B, Lee JY, Bergman T, Carlquist M, Boman HG, et al. (1991) Amino acid sequence of PR-39. Isolation from pig intestine of a new member of the family of proline-arginine-rich antibacterial peptides. Eur J Biochem 202: 849-854.
11. Brogden KA (2005) Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 3: 238-250.
12. Lohner K, Blondelle SE (2005) Molecular mechanisms of membrane perturbation by antimicrobial peptides and the use of biophysical studies in the design of novel peptide antibiotics. Comb Chem High Throughput Screen 8: 241-256.
13. Tossi A, Sandri L (2002) Molecular diversity in gene-encoded, cationic antimicrobial polypeptides. Curr Pharm Des 8: 743-761.
14. Beisswenger C, Bals R (2005) Functions of antimicrobial peptides in host defense and immunity. Curr Protein Pept Sci 6: 255-264.
15. Yang D, Biragyn A, Hoover DM, Lubkowski J, Oppenheim JJ (2004) Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu Rev Immunol 22: 181-215.
16. Elsbach P (2003) What is the real role of antimicrobial polypeptides that can mediate several other inflammatory responses? J Clin Invest 111: 1643-1645.
17. Nordahl EA, Rydenga rd V, Nyberg P, Nitsche DP, Mörgelin M, et al. (2004) Activation of the complement system generates antibacterial peptides. Proc Natl Acad Sci U S A 101: 16879-16884.
18. Nordahl EA, Rydengard V, Mörgelin M, Schmidtchen A (2005) Domain 5 of high molecular weight kininogen is antibacterial. J Biol Chem 280: 34832-34839.
19. Frick IM, Akesson P, Herwald H, Morgelin M, Malmsten M, et al. (2006) The contact system-a novel branch of innate immunity generating antibacterial peptides. Embo J 25: 5569-5578.
20. Pereira HA (1995) CAP37, a neutrophil-derived multifunctional inflammatory mediator. J Leukoc Biol 57: 805-812.
21. Malmsten M, Davoudi M, Walse B, Rydengard V, Pasupuleti M, et al. (2007) Antimicrobial peptides derived from growth factors. Growth Factors 25: 60-70.
22. Malmsten M, Davoudi M, Schmidtchen A (2006) Bacterial killing by heparinbinding peptides from PRELP and thrombospondin. Matrix Biol 25: 294-300.
23. Pasupuleti M, Roupe M, Rydengard V, Surewicz K, Surewicz WK, et al. (2009) Antimicrobial activity of human prion protein is mediated by its N-terminal region. PLoS One 4: e7358.
24. Nilsson M, Wasylik S, Morgelin M, Olin AI, Meijers JC, et al. (2008) The antibacterial activity of peptides derived from human beta-2 glycoprotein I is inhibited by protein H and M1 protein from Streptococcus pyogenes. Mol Microbiol 67: 482-492.
25. Rydengard V, Shannon O, Lundqvist K, Kacprzyk L, Chalupka A, et al. (2008) Histidine-rich glycoprotein protects from systemic Candida infection. PLoS Pathog 4: e1000116.
26. Papareddy P, Rydengard V, Pasupuleti M, Walse B, Morgelin M, et al. (2010) Proteolysis of human thrombin generates novel host defense peptides. PLoS Pathog 6: e1000857.
27. Papareddy P, Kalle M, Kasetty G, Morgelin M, Rydengard V, et al. (2010) Cterminal peptides of tissue-factor pathway inhibitor are novel host defense molecules. J Biol Chem 285: 28387-28398.
28. Cardin AD, Weintraub HJ (1989) Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 9: 21-32.
29. Andersson E, Rydengard V, Sonesson A, Morgelin M, Bjorck L, et al. (2004) Antimicrobial activities of heparin-binding peptides. Eur J Biochem 271: 1219-1226.
30. Ringstad L, Schmidtchen A, Malmsten M (2006) Effect of peptide length on the interaction between consensus peptides and DOPC/DOPA bilayers. Langmuir 22: 5042-5050.
31. Woodford N, Livermore DM (2009) Infections caused by Gram-positive bacteria: a review of the global challenge. J Infect 59 Suppl 1: S4-16.
32. Amyes SG (2007) Enterococci and streptococci. Int J Antimicrob Agents 29 Suppl 3: S43-52.
33. Kunz AN, Brook I (2010) Emerging Resistant Gram-Negative Aerobic Bacilli in Hospital-Acquired Infections. Chemotherapy 56: 492-500.
34. Vermeulen H, van Hattem JM, Storm-Versloot MN, Ubbink DT (2007) Topical silver for treating infected wounds. Cochrane Database Syst Rev. CD005486.
35. Marr AK, Gooderham WJ, Hancock RE (2006) Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr Opin Pharmacol.
36. Fritsche TR, Rhomberg PR, Sader HS, Jones RN (2008) Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections. J Antimicrob Chemother 61: 1092-1098.
37. Schmidtchen A, Holst E, Tapper H, Bjorck L (2003) Elastase-producing Pseudomonas aeruginosa degrade plasma proteins and extracellular products of human skin and fibroblasts, and inhibit fibroblast growth. Microb Pathog 34: 47-55.
38. Werthen M, Davoudi M, Sonesson A, Nitsche DP, Morgelin M, et al. (2004) Pseudomonas aeruginosa-induced infection and degradation of human wound fluid and skin proteins ex vivo are eradicated by a synthetic cationic polymer. J Antimicrob Chemother 54: 772-779.
39. Nizet V (2007) Understanding how leading bacterial pathogens subvert innate immunity to reveal novel therapeutic targets. J Allergy Clin Immunol 120: 13-22.
40. Foster TJ (2005) Immune evasion by staphylococci. Nat Rev Microbiol 3: 948-958.
41. Peschel A, Sahl HG (2006) The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nat Rev Microbiol 4: 529-536.
42. Blondelle SE, Lohner K (2000) Combinatorial libraries: a tool to design antimicrobial and antifungal peptide analogues having lytic specificities for structure-activity relationship studies. Biopolymers 55: 74-87.
43. Sajjan US, Tran LT, Sole N, Rovaldi C, Akiyama A, et al. (2001) P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients. Antimicrob Agents Chemother 45: 3437-3444.
44. Fernandez-Lopez S, Kim HS, Choi EC, Delgado M, Granja JR, et al. (2001) Antibacterial agents based on the cyclic D,L-alpha-peptide architecture. Nature 412: 452-455.
45. Hilpert K, Volkmer-Engert R, Walter T, Hancock RE (2005) High-throughput generation of small antibacterial peptides with improved activity. Nat Biotechnol 23: 1008-1012.
46. Taboureau O, Olsen OH, Nielsen JD, Raventos D, Mygind PH, et al. (2006) Design of novispirin antimicrobial peptides by quantitative structure-activity relationship. Chem Biol Drug Des 68: 48-57.
47. Jenssen H, Lejon T, Hilpert K, Fjell CD, Cherkasov A, et al. (2007) Evaluating different descriptors for model design of antimicrobial peptides with enhanced activity toward P. aeruginosa. Chem Biol Drug Des 70: 134-142.
48. Pasupuleti M, Walse B, Svensson B, Malmsten M, Schmidtchen A (2008) Rational design of antimicrobial C3a analogues with enhanced effects against Staphylococci using an integrated structure and function-based approach. Biochemistry 47: 9057-9070.
49. Pasupuleti M, Walse B, Nordahl EA, Morgelin M, Malmsten M, et al. (2007) Preservation of antimicrobial properties of complement peptide C3a, from invertebrates to humans. J Biol Chem 282: 2520-2528.
50. Nordahl EA, Rydengard V, Nyberg P, Nitsche DP, Morgelin M, et al. (2004) Activation of the complement system generates antibacterial peptides. Proc Natl Acad Sci U S A 101: 16879-16884.
51. Nordahl EA, Rydengard V, Morgelin M, Schmidtchen A (2005) Domain 5 of high molecular weight kininogen is antibacterial. J Biol Chem 280: 34832-34839.
52. Malmsten M, Davoudi M, Walse B, Rydengard V, Pasupuleti M, et al. (2007) Antimicrobial peptides derived from growth factors. Growth Factors 25: 60-70.
53. Hancock RE, Sahl HG (2006) Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 24: 1551-1557.
54. Marr AK, Gooderham WJ, Hancock RE (2006) Antibacterial peptides fortherapeutic use: obstacles and realistic outlook. Curr Opin Pharmacol 6: 468-472.
55. Schmidtchen A, Pasupuleti M, Morgelin M, Davoudi M, Alenfall J, et al. (2009) Boosting antimicrobial peptides by hydrophobic oligopeptide end tags. J Biol Chem 284: 17584-17594.
56. Pasupuleti M, Chalupka A, Morgelin M, Schmidtchen A, Malmsten M (2009) Tryptophan end-tagging of antimicrobial peptides for increased potency against Pseudomonas aeruginosa. Biochim Biophys Acta 1790: 800-808.
57. Pasupuleti M, Schmidtchen A, Chalupka A, Ringstad L, Malmsten M (2009) End-tagging of ultra-short antimicrobial peptides by W/F stretches to facilitate bacterial killing. PLoS One 4: e5285.
58. Lehrer RI, Rosenman M, Harwig SS, Jackson R, Eisenhauer P (1991) Ultrasensitive assays for endogenous antimicrobial polypeptides. J Immunol Methods 137: 167-173.
59. Andersson E, Rydenga rd V, Sonesson A, Mörgelin M, Björck L, et al. (2004) Antimicrobial activities of heparin-binding peptides. Eur J Biochem 271: 1219-1226.
60. Wiegand I, Hilpert K, Hancock RE (2008) Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc 3: 163-175.
61. McDonnell G, Haines K, Klein D, Rippon M, Walmsley R, et al. (1999) Clinical correlation of a skin antisepsis model. J Microbiol Methods 35: 31-35.
62. Nizet V (2006) Antimicrobial peptide resistance mechanisms of human bacterial pathogens. Curr Issues Mol Biol 8: 11-26.
63. Huang HW (2006) Molecular mechanism of antimicrobial peptides: the origin of cooperativity. Biochim Biophys Acta 1758: 1292-1302.
64. Stromstedt AA, Wessman P, Ringstad L, Edwards K, Malmsten M (2007) Effect of lipid headgroup composition on the interaction between melittin and lipid bilayers. J Colloid Interface Sci 311: 59-69.
65. Ramamoorthy A, Thennarasu S, Lee DK, Tan A, Maloy L (2006) Solid-state NMR investigation of the membrane-disrupting mechanism of antimicrobial peptides MSI-78 and MSI-594 derived from magainin 2 and melittin. Biophys J 91: 206-216.
66. Ringstad L, Andersson Nordahl E, Schmidtchen A, Malmsten M (2007) Composition Effect on Peptide Interaction with Lipids and Bacteria: Variants of C3a Peptide CNY21. Biophys J 92: 87-98.
67. Ringstad L, Kacprzyk L, Schmidtchen A, Malmsten M (2007) Effects of topology, length, and charge on the activity of a kininogen-derived peptide on lipid membranes and bacteria. Biochim Biophys Acta 1768: 715-727.
68. Ringstad L, Protopapa E, Lindholm-Sethson B, Schmidtchen A, Nelson A, et al. (2008) An electrochemical study into the interaction between complementderived peptides and DOPC mono- and bilayers. Langmuir 24: 208-216.
69. Chen FY, Lee MT, Huang HW (2003) Evidence for membrane thinning effect as the mechanism for peptide-induced pore formation. Biophys J 84: 3751-3758.
70. Li X, Li Y, Peterkofsky A, Wang G (2006) NMR studies of aurein 1.2 analogs. Biochim Biophys Acta 1758: 1203-1214.
71. McDonnell G, Russell AD (1999) Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev 12: 147-179.
72. Poon VK, Burd A (2004) In vitro cytotoxity of silver: implication for clinical wound care. Burns 30: 140-147.